Safety and Efficacy of the BTL-699 Device for Temporary Reduction of Food Cravings
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 29
- 试验地点
- 2
- 主要终点
- Assessment of Change in Food Cravings
研究概览
简要总结
The goal of this clinical trial is to evaluate if the treatment with BTL-699 device is able to temporarily reduce food cravings in adults above the age of 22 years. The main question it aims to answer is:
Does the treatment with BTL-699 device provide a temporary reduction of food cravings?
Participants will be asked to:
- Undergo 4 to 6 treatments
- Undergo weight measurements
- Complete the Food Cravings Questionnaire-Trait
- Complete the Therapy Comfort Questionnaire
- Complete the Satisfaction Questionnaire
详细描述
This study uses a single-center, single-arm, open-label, interventional design.
Subjects reporting at least 3 to 5 weekly instances of food cravings will be enrolled. All enrolled participants will receive 4 to 6 treatments with the BTL-699 device, administered 2 to 3 days apart. The required number of treatments for each participant will be determined on a case-by-case basis by the Principal Investigator, with a minimum of four sessions.
Therapy parameters will be adjusted based on patient feedback and comfort, up to 100% of the individual's motor threshold.
Examination for possible adverse effects will be assessed at each visit.
The Food Cravings Questionnaire-Trait will be administered before the first treatment, after the last treatment, and at the two follow-up visits-2 weeks and 1 month after the final session.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •At least 3-5 self-reported episodes of food craving periods per week
- •Age > 22 years
- •Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the right thumb at least five out of 10 times
- •Subjects willing and able to abstain from partaking in any other weight management treatments other than the study procedure during study participation
- •Willingness to comply with study instructions and to return to the clinic for the required visits
排除标准
- •Cochlear implants
- •Intake disorders such as bulimia, anorexia
- •Borderline personality disorder
- •Other metal implants close to the application area (1 meter at least)
- •Personal history of epilepsy
- •Personal history of syncope
- •Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without a history of seizure, and without anticonvulsant medication
- •Sleep deprivation
- •Alcoholism
- •Presence of a substance abuse or dependence (alcohol, caffeine, drugs) conditions associated with altered seizure risk
- •Intake of one or a combination of the following drugs forms a strong potential hazard for the application of rTMS due to their significant seizure threshold lowering potential: imipramine, amitriptyline, doxepine, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel's dust), ketamine, gamma-hydroxybutyrate (GHB), alcohol, theophylline
- •Intake of seizure threshold lowering drugs such as: mianserin, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, reboxetine, venlafaxine, duloxetine, bupropion, mirtazapine, fluphenazine, pimozide, haloperidol, olanzapine, quetiapine, aripiprazole, ziprasidone, risperidone, chloroquine, mefloquine, imipenem, penicillin, ampicillin, cephalosporins, metronidazole, isoniazid, levofloxacin, cyclosporin, chlorambucil, vincristine, methotrexate, cytosine arabinoside, BCNU, lithium, anticholinergics, antihistamines, sympathomimetics
- •Withdrawal from one of the following drugs could form a relative hazard for the application of rTMS due to the resulting significant seizure threshold lowering potential: alcohol, barbiturates, benzodiazepines, meprobamate, chloralhydrate
- •Systemic infection, fever
- •Patients with a broad range of neuropsychiatric diseases are at elevated risk for seizures. - Essentially all neurologic conditions with structural cerebral damage (e.g. stroke, multiple sclerosis, traumatic brain injury, Alzheimer's and other neurodegenerative diseases, meningoencephalitis or intracerebral abscess, parenchymal or leptomeningeal cancers) are associated with an elevated risk for seizures
- •Major depression (elevated seizure risk)
- •Hyponatremia, hypocalcemia, hypomagnesemia, hypoglycemia, hyperglycemia, renal failure/uremia, liver failure
- •Raised blood concentrations of pro-convulsant medications due to reduced clearance (e.g. secondary to initiation of antibiotics for treatment of infections)
- •Immunosuppressive therapy with cyclosporine, tacrolimus and other agents that can cause the posterior reversible leukoencephalopathy syndrome
- •Bipolar Disorder
- •Pregnancy or lactation, absence of medically approved contraceptive methods in females of childbearing potential
- •Urine drug screen positive for amphetamines, barbiturates, cannabinoids, cocaine metabolites, opiates and phencyclidine
- •Implanted infusion pumps
- •Intracardiac devices (pacemakers, heart valves, etc.)
- •Contradictions for the testing used in the trial, for example, the motor threshold cannot be found or quantified
结局指标
主要结局
Assessment of Change in Food Cravings
时间窗: 15 months
The change in the score obtained from the Food Cravings Questionnaire-Trait will be recorded. The questionnaire will be administered at the baseline visit, after the last treatment, at the 2-week and 1-month follow-up visits. The score ranges from 39 to 234 and higher scores indicate more frequent and intense food cravings in general. An improvement is defined as a decrease in score.
次要结局
- Assessment of Therapy Comfort(15 months)
- Assessment of Satisfaction(15 months)
- Incidence of Treatment-related Adverse Events(15 months)